In this Issue
- Q4’24: Federal Psychedelics Lobbying Update
- GH Research Discusses Lack of Placebo Effect, Decision to Keep Trial Sites Secret
- Virginia Lawmakers Question Purpose and Precedent of Compass Pathways’ Rescheduling Bill
- VA Psychedelics Champion Leaves Post
- Colorado’s Psychedelics Program Sees Slow Start
- Lykos’ FDA Rejection in Context
- Center for MINDS Backs Psilocybin for Creativity Study
- Study Reveals Differing Views on Psychological Support
- Other Stories, Including: Soaring atai Life Sciences Stock Tempered By Public Offering; American Society of Anesthesiologists Issues Guidance on Ketamine for Mental Health; MAPS Looks for New Exec. Director, Suffers Twitter Hack; Trump’s Latest DEA Pick Appears Tough on Marijuana; Lawsuit Alleges Drug Use Culture at Dr. Bronner’s Led to Employee’s Death; UK Parliamentary Office of Science and Technology Issues Psychedelics Briefing; Court of Appeals Affirms DEA Denial of Psilocybin Right to Try Request…
***
Q4’24: Federal Psychedelics Lobbying Update
Q4 2024 lobbying disclosure forms have now been filed, so we are taking a quick look at updates since our last review.
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
